Multaq and Hepatic encephalopathy - a phase IV clinical study of FDA data

Summary:

Hepatic encephalopathy is reported as a side effect among people who take Multaq (dronedarone hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Formoterol Fumarate, and have Osteoporosis.

The phase IV clinical study analyzes which people have Hepatic encephalopathy when taking Multaq. It is created by eHealthMe based on reports of 10,572 people who have side effects when taking Multaq from the FDA, and is updated regularly.

What is Multaq?

Multaq has active ingredients of dronedarone hydrochloride. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 11,053 Multaq users. Check the latest studies of Multaq.

What is Hepatic encephalopathy?

Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure) is found to be associated with 913 drugs and 1,259 conditions by eHealthMe. Check the latest studies of Hepatic encephalopathy.

On Jul, 10, 2026

10,572 people reported to have side effects when taking Multaq.
Among them, 20 people (0.19%) have Hepatic encephalopathy.

Could Multaq cause Hepatic encephalopathy?

Among these 20 people:

How long have people been on Multaq when they have Hepatic encephalopathy? *

What is the gender of people who have Hepatic encephalopathy when taking Multaq? *

female: 65 %
male: 35 %

What is the age of people who have Hepatic encephalopathy when taking Multaq? *

What are other drugs people take besides Multaq? *

What are other side effects people have besides Hepatic encephalopathy? *

Jaundice - Yellow Skin (a yellowish pigmentation of the skin): 12 people, 60.00%
Acute Hepatic Failure: 9 people, 45.00%
Weakness: 8 people, 40.00%
Abdominal Pain: 7 people, 35.00%
Acute Kidney Failure: 7 people, 35.00%
Ascites (accumulation of fluid in the abdominal cavity): 7 people, 35.00%
Hepatic Failure (liver failure): 6 people, 30.00%
Blood Bilirubin Increased: 6 people, 30.00%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 5 people, 25.00%
Diarrhea: 5 people, 25.00%

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 6 people, 30.00%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 5 people, 25.00%
Heart Attack: 1 person, 5.00%
Asthma: 1 person, 5.00%
Acne (skin problems that cause pimples): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Multaq and have Hepatic encephalopathy?

- Check whether Hepatic encephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Multaq:

Multaq (11,053 reports)

Browse all side effects of Multaq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic encephalopathy:

Hepatic encephalopathy (913 drugs)

Browse all the conditions that are associated with Hepatic encephalopathy:

Hepatic encephalopathy (1,259 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dronedarone hydrochloride (the active ingredients of Multaq) and Multaq (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.